Profiling cell identity and tissue architecture with single-cell and spatial transcriptomics

GS Gulati, JP D'Silva, Y Liu, L Wang… - … Reviews Molecular Cell …, 2024 - nature.com
Single-cell transcriptomics has broadened our understanding of cellular diversity and gene
expression dynamics in healthy and diseased tissues. Recently, spatial transcriptomics has …

Map** the genomic diaspora of gastric cancer

KG Yeoh, P Tan - Nature reviews cancer, 2022 - nature.com
Gastric cancer (GC) is a leading contributor to global cancer incidence and mortality.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

NL de Vries, J van de Haar, V Veninga, M Chalabi… - Nature, 2023 - nature.com
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade …

Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity

PMK Westcott, F Muyas, H Hauck, OC Smith… - Nature Genetics, 2023 - nature.com
DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability–high gastric or esophagogastric …

T André, D Tougeron, G Piessen… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ)
adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard …

Advances in single-cell RNA sequencing and its applications in cancer research

D Huang, N Ma, X Li, Y Gou, Y Duan, B Liu… - Journal of hematology & …, 2023 - Springer
Cancers are a group of heterogeneous diseases characterized by the acquisition of
functional capabilities during the transition from a normal to a neoplastic state. Powerful …

The new era of immunotherapy in gastric cancer

S Takei, A Kawazoe, K Shitara - Cancers, 2022 - mdpi.com
Simple Summary Advanced gastric cancer remains a malignancy with a poor prognosis,
with a median survival of about 12–15 months. In recent years, immune checkpoint inhibitors …

[HTML][HTML] Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer

Z Lin, M Cai, P Zhang, G Li, T Liu, X Li… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background In locally advanced rectal cancer (LARC), preoperative short-course
radiotherapy (SCRT) with delayed surgery has been shown to be as effective as long-course …

Early tumor–immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer

R Kim, M An, H Lee, A Mehta, YJ Heo, KM Kim, SY Lee… - Cancer discovery, 2022 - AACR
Chemotherapy is ubiquitous in first-line treatment of advanced gastric cancer, yet responses
are heterogeneous, and little is known about mediators of chemotherapy response. To move …

Tumour mutational burden: clinical utility, challenges and emerging improvements

J Budczies, D Kazdal, M Menzel, S Beck… - Nature Reviews …, 2024 - nature.com
Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous
mutations present within the cancer genome, varies across and within cancer types. A first …